Categories: DeliveryDevelopmentDrugScienceTechnology
PulseSight is an ophthalmology drug development company developing disruptive non-viral gene therapies with minimally-invasive delivery technology to treat major eye diseases. Our mission is to develop life-changing solutions for patients with diseases leading to sight loss.
Investors 2
Mentions in press and media 4
| Date | Title | Description |
| 22.01.2026 | Dosing completed in the Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA) | - |
| 13.02.2025 | PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical Development of PST-611 in dry AMD | PARIS, Feb. 13, 2025 (GLOBE NEWSWIRE) — PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its S... |
| 07.10.2024 | PulseSight Therapeutics to Present Data on PST-611 at EVER Congress 2024 | PARIS, Oct. 07, 2024 (GLOBE NEWSWIRE) — PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, is pleased to confirm that it will be pr... |
| 28.02.2024 | PulseSight Therapeutics Raises Seed Funding | PulseSight Therapeutics, a Paris, France-based ophthalmology biotech company, raised an undisclosed amount in Seed funding.
The round was led by Pureos Bioventures and ND Capital, with participation from Korea Investment Partners.
The compa... |
Reviews 0
